SCHEMBL25237125

SCHEMBL25237125

Cn1ncc2c(S)ncnc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.63
PI4K2B Q8TCG2 1/20 0.63
PI4K2A Q9BTU6 1/20 0.63
PI4KB Q9UBF8 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 3/20 0.54
ALOX15 P16050 1/20 0.54
NSD2 O96028 1/20 0.53
PKM P14618 1/20 0.53
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HAVCR2 Q8TDQ0 1/20 0.49
TP53 P04637 2/20 0.47
HTT P42858 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25605061 0.78 PI4KA (0.61) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL12826084 0.78 PI4KA (0.61) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL12766976 0.75 PI4KA (0.58) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL21348442 0.75 SMN1; SMN2 (0.58) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL850318 0.75 GSK3B (0.39) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL29854071 0.75 KDM4E (0.68) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL20276307 0.75 PI4KA (0.58) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL21851658 0.75 ALDH1A1 (0.58) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL29935739 0.73 PI4KA (0.56) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2
SCHEMBL23996445 0.72 PI4KA (0.54) PI4KAPI4K2BPI4K2API4KBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 EP disclosed
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors AUGUSTINE THERAPEUTICS (BE) 2025-09-23 US disclosed
US-20250145604-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2025-05-08 US disclosed
US-20250051319-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2025-02-13 US disclosed
WO-2024261329-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 WO disclosed
EP-4452265-A2 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2024-10-30 EP disclosed
CN-118591375-A Compounds as HDAC6 inhibitors and uses thereof 奥古斯汀治疗公司 2024-09-03 CN disclosed
WO-2023118507-A2 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2023-06-29 WO disclosed
WO-2023118507-A2 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051319-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS HDAC6, HDAC9, HDAC1 PI4KA 3244/4885PI4K2B 2025/4885PI4K2A 2553/4885
US-20250145604-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS HDAC6, HDAC9, HDAC1 PI4KA 3244/4885PI4K2B 2025/4885PI4K2A 2553/4885
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors HDAC6, HDAC9, HDAC1 PI4KA 3041/4885PI4K2B 2012/4885PI4K2A 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.